Neoadjuvant endocrine therapy of breast cancer: which patients would benefit and what are the advantages?

By Takei Hiroyuki  

Breast Cancer, Vol. 18, Iss. 2, 2011-04 ,pp. : 85-91

Springer Publishing Company

Access to resources Recommend Favorite

Drug switch because of treatment-related adverse side effects in endocrine adjuvant breast cancer therapy: how often and how often does it work?

By Güth Uwe  

Breast Cancer Research and Treatment, Vol. 129, Iss. 3, 2011-10 ,pp. : 799-807

Springer Publishing Company

Access to resources Recommend Favorite

Direct comparisons of adjuvant endocrine therapy, chemotherapy, and chemoendocrine therapy for operable breast cancer patients stratified by estrogen receptor and menopausal status

By Nomura Yasuo   Shirouzu Mitsunori   Takayama Takahiro  

Breast Cancer Research and Treatment, Vol. 49, Iss. 1, 1998-05 ,pp. : 51-60

Springer Publishing Company

Access to resources Recommend Favorite

Prognostic value of Bcl-2 in two independent populations of estrogen receptor positive breast cancer patients treated with adjuvant endocrine therapy

By Larsen Mathilde S.   Bjerre Karsten   Giobbie-Hurder Anita   Lænkholm Anne-Vibeke   Henriksen Katrine L.   Ejlertsen Bent   Lykkesfeldt Anne E.   Rasmussen Birgitte B.  

Acta Oncologica, Vol. 51, Iss. 6, 2012-07 ,pp. : 781-789

Informa Healthcare

Access to resources Recommend Favorite

Weight gain associated with adjuvant tamoxifen therapy in stage I and II breast cancer: fact or artifact?

By Kumar N.B.  

Breast Cancer Research and Treatment, Vol. 44, Iss. 2, 1997-06 ,pp. : 135-143

Springer Publishing Company

Access to resources Recommend Favorite